Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Chronic Pulmonary Aspergillosis and Ambisome Aerosol With Itraconazole

This study compares the therapeutic (clinical and radiological) efficacy of a six-month treatment by itraconazole and nebulised Ambisome® (liposomal amphotericin B = LAmB) versus treatment by

  • 16 views
  • 23 Mar, 2022
  • 1 location
Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

This is a Phase 1, single-center, nonrandomized, open-label, 2-part, fixed-sequence, drug-drug interaction (DDI) study to assess the effect of multiple doses of itraconazole, a CYP3A4 enzyme

Accepts healthy volunteers
  • 0 views
  • 01 Jul, 2022
  • 1 location
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

This is a Phase 1, open-label, non-randomised, 3-arm (A, B, and C), drug-drug interaction study in patients with advanced solid tumours.

  • 0 views
  • 09 Jun, 2022
  • 4 locations
Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants

The main purpose of this study is to learn about how itraconazole and carbamazepine affect the levels of LY3410738 in the blood stream of healthy participants. Participation could last up to 75

Accepts healthy volunteers
  • 0 views
  • 02 Jul, 2022
  • 1 location
A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants

The purpose of this study is to evaluate the effect of co-administration of itraconazole or verapamil on the drug levels of MYK-224 in healthy participants.

Accepts healthy volunteers
  • 0 views
  • 01 Jul, 2022
  • 1 location
A Randomized Controlled Trial to Compare the Clinical Outcomes With Six Months of Therapy With Oral Itraconazole Versus Oral Voriconazole for Management of Treatment naïve Subjects With Chronic Pulmonary Aspergillosis

The current initial therapy for CPA is with six months of oral itraconazole. However, the response with six months of therapy has a response rate of 65-70% and has a relapse rate after stopping

  • 7 views
  • 28 Jun, 2022
  • 1 location
PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

A Phase 1 Open-label, Two-cohort, One-sequence Crossover Study to Investigate the Effect of P glycoprotein Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics, Safety, and

Accepts healthy volunteers
  • 0 views
  • 16 Mar, 2022
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Prospective, open-label, two-way crossover, phase Ib drug-drug interaction study in patients with advanced solid tumors

  • 0 views
  • 07 Oct, 2021
  • 2 locations
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents

Atrial fibrillation patients with risk factors for stroke and systemic embolism require long-term anticoagulant therapy. Recently, non-vitamin K antagonist oral anticoagulant (NOAC) has shown their excellent safety and efficacy, and thus are widely accepted in clinical practice. Meanwhile, after percutaneous coronary intervention (PCI) using the drug-eluting stents due to coronary …

embolism
vitamin k antagonist
stroke
anticoagulant therapy
warfarin
  • 0 views
  • 23 Sep, 2021
  • 1 location
A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection

This study will provide: (1) new insights in the prevalence of Aspergillus infection in children and adolescents with CF aged 8-17 yrs; (2) an in silico modelled dose of posaconazole for children and adolescents with CF and Aspergillus infection aged 8-17 yrs; (3) an intensive sampling PK study to define …

voriconazole
fibrosis
posaconazole
itraconazole
respiratory symptom
  • 10 views
  • 26 Jul, 2021
  • 31 locations